You are here

Yale Researchers Beat Untreatable Eczema With Arthritis Drug

Tofacitinib citrate interrupts immune response

Researchers at the Yale School of Medicine have successfully treated patients with moderate-to-severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report.

The findings were published online in the Journal of the American Academy of Dermatology.

Eczema (atopic dermatitis) is a chronic condition that causes severe itching and leaves the skin red and thickened. It can adversely affect sleep and quality of life. Standard treatments, such as steroid creams and oral medicines, commonly fail to relieve symptoms in patients with moderate-to-severe eczema.

Based on current scientific models of eczema biology, assistant professor of dermatology Brett King, MD hypothesized that a drug approved for rheumatoid arthritis, tofacitinib citrate, would interrupt the immune response that causes eczema.

In the new study, King and his colleagues report that treatment with the drug led to a dramatic improvement in six patients with moderate-to-severe eczema who had previously tried conventional therapies without success. During treatment, all six patients reported significant reductions in itching as well as improved sleep. The redness and thickening of the skin diminished as well.

King and fellow Yale dermatologist Brittany Craiglow, MD, had previously shown that tofacitinib citrate regrows hair in patients with alopecia areata, an autoimmune-related form of hair loss. They also published findings reporting the successful treatment of a patient with vitiligo, which can leave widespread irregular white patches all over the body.

The new study suggests that a change in the standard of care for eczema –– a condition for which there is no targeted therapy –– may be on the horizon, the researchers say.

They note that further research is needed to confirm the treatment’s long-term efficacy and safety in eczema patients.

Source: Yale News; July 20, 2015.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels